webinar register page

Webinar banner
The ability to claim larger health system productivity benefits from the introduction of chronic disease medicines looms in importance as these therapeutic segments become more crowd
Category: Pharma
> Chronic Diseases

Moderator:
> Katherine Vandebelt
Global Vice President, Clinical Innovation, Oracle Health Science

Panelists:
> Douglas Schlichting, RN, PhD
Development Director Immunology Product Development – baricitinib rheumatoid arthritis and COVID-19, Eli Lilly and Company
> David Platt, MD
Vice President, Medical Unit Head
Cardiovascular, Renal & Metabolism Medical Unit, Novartis Pharmaceuticals Corporation
> Dr. Sandi See Tai
VP, Medicine Team Lead for Amyloid, Rare Neuro & Cardiac, Pfizer Global Product Development, Pfizer Inc.
> Sailaja Bhaskar, BPharm, MS, PhD, MBA
Executive Director, Clinical Operations Planning, Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P.
> Eric M Pearlman
Senior Medical Director-Neuroscience, US Medical Affairs, Eli Lilly and Company

Oct 28, 2020 11:00 AM in Eastern Time (US and Canada)

Webinar logo
* Required information
Loading

By registering, I agree to the Privacy Statement and Terms of Service.

Register